Safety and potential benefit of hyperthermic intraperitoneal chemotherapy (HIPEC) in peritoneal carcinomatosis from primary or recurrent ovarian cancer

✍ Scribed by Franco Roviello; Enrico Pinto; Giovanni Corso; Corrado Pedrazzani; Stefano Caruso; Marco Filippeschi; Roberto Petrioli; Stefania Marsili; Maria Antonietta Mazzei; Daniele Marrelli

• Publisher: John Wiley and Sons
• Year: 2010
• Tongue: English
• Weight: 183 KB
• Volume: 102
• Category: Article
• ISSN: 0022-4790
• DOI: 10.1002/jso.21682

✦ Synopsis

Abstract

Objectives

To analyze the outcomes of cytoreductive surgery and HIPEC in patients with peritoneal carcinomatosis from ovarian cancer.

Methods

Fifty‐three patients with peritoneal carcinomatosis from primary (45 cases) and recurrent (8 cases) ovarian cancer were previously treated by systemic chemotherapy with platinum and taxanes and then submitted to surgical cytoreduction and HIPEC (cisplatin and mitomycin‐C) with a closed abdomen technique. The median follow‐up period was 27 months (range: 3–107).

Results

At the end of operation a complete cytoreduction (CCR‐0) was obtained in 37 patients (70%). Major morbidity occurred in 12 patients (23%); reoperation was necessary in 2 patients (4%), and no postoperative mortality was observed. Overall 5‐year survival probability was 55%; it was 71% in CCR‐0, 44% in CCR‐1, and none in patients with CCR‐2 or CCR‐3 residual tumor (log‐rank test: P = 0.017). The cumulative risk of recurrence in 37 CCR‐0 cases was 54% at 5 years from operation.

Conclusions

The results of our study indicate the feasibility and the potential benefit of a protocol including systemic chemotherapy, surgical cytoreduction and HIPEC in patients with peritoneal carcinomatosis from ovarian cancer. A phase III trial to compare this approach with conventional treatment is needed. J. Surg. Oncol. 2010;102:663–670. © 2010 Wiley‐Liss, Inc.